News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avinger, Inc. Completes Enrollment of PAD-Focused CONNECT II Global Clinical Trial



6/12/2012 10:37:58 AM

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for treating patients with peripheral artery disease (PAD), announced that it has successfully completed enrollment in its CONNECT II global clinical trial. PAD is a silent epidemic that affects 8 to 12 million adults in the U.S., 30 million globally and is the leading cause of amputation in patients over 50. A study published in the January 2012 American Heart Association journal Circulation claims that PAD is an unsung “pandemic” that afflicts even more women than men.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES